Schreiberhuber, Lena
Barrett, James E.
Wang, Jiangrong
Redl, Elisa http://orcid.org/0000-0001-6540-8443
Herzog, Chiara http://orcid.org/0000-0002-1572-498X
Vavourakis, Charlotte D. http://orcid.org/0000-0002-5027-2309
Sundström, Karin http://orcid.org/0000-0002-6865-0224
Dillner, Joakim http://orcid.org/0000-0001-8588-6506
Widschwendter, Martin http://orcid.org/0000-0002-7778-8380
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (874662, 874662)
The Land Tirol
Article History
Received: 19 January 2024
Accepted: 23 April 2024
First Online: 4 June 2024
Competing interests
: J.E.B. and M.W. are named as inventors on a patent (submitted by University College London Business Ltd (UCLB); no. WO2021255460), which covers developmental aspects of the WID-qCIN test. M.W., L.S. and E.R. are listed as inventors on a priority patent application (submitted by Sola Diagnostics GmbH; no. GB2401477.1) covering the optimization of the WID-qCIN test. J.E.B., C.H. and M.W. are shareholders in Sola Diagnostics GmbH, which holds exclusive licenses to the respective intellectual property rights that protect the commercialization of the WID-qCIN test. K.S. has received consulting fees and research grants from Merck Sharp and Dohme Corp. to her affiliating institution for studies on HPV vaccination in Sweden. The other authors declare no competing interests.